Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.34 |
| ▸ | USP1 | O94782 | 13/20 | 0.34 |
| ▸ | WDR48 | Q8TAF3 | 7/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22094175 | 1.00 | NOTUM (0.34) | NOTUMUSP1WDR48USP7ADRB2 | |
| SCHEMBL22094765 | 0.85 | NOTUM (0.37) | NOTUMUSP1WDR48USP7ADORA2A | |
| SCHEMBL22095030 | 0.78 | MEN1 (0.34) | ADRB2 | |
| SCHEMBL22095076 | 0.70 | NOTUM (0.39) | NOTUMADORA2AADORA1CYP19A1 | |
| SCHEMBL31309043 | 0.70 | NOTUM (0.39) | NOTUMADORA2AADORA1CYP19A1 | |
| SCHEMBL25003928 | 0.70 | NOTUM (0.40) | NOTUMUSP1WDR48ADORA2AADORA1 | |
| SCHEMBL31309104 | 0.68 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL22094055 | 0.68 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL22094548 | 0.65 | TP53 (0.40) | NOTUMCYP19A1 | |
| SCHEMBL31308705 | 0.65 | TP53 (0.40) | NOTUMCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113923988-B | Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2024-12-13 | — | — | CN | disclosed |